Daniel Katzman
Executive at Precision Virologics · Executive Officer, Director at Unleash Immuno Oncolytics
St. Louis, Missouri
Find your path to Daniel
12 people in our graph share verified history with Daniel — schools, employers, funds. One of them is your warm intro.
About
Daniel Katzman is CEO and founder of Unleash Immuno Oncolytics, which he built from formation through platform development to a transaction with TransCode Therapeutics (Nasdaq: RNAZ) granting TransCode exclusive worldwide rights to its oncolytic virus candidates UIO-524, UIO-525, and UIO-526 and associated intellectual property. The lead program, UIO-524, was designed to target malignant cells and the tumor microenvironment with an initial focus on muscle-invasive bladder cancer. He is also co-founder and Chairman of Asclepii, a Cleveland-based medical technology company developing regenerative medicine products for advanced wound care, where he works on corporate strategy, financing, partnerships, intellectual property, and commercialization.
Executive at Precision Virologics
Executive Officer, Director at Unleash Immuno Oncolytics
Experience
- Unleash Immuno OncolyticsCEO and Foundercurrent2015 — present
- AsclepiiChairman and Co-Foundercurrent2022 — presentCleveland, OH
- SmarterGuest / SmarterFlowPartnercurrent2013 — present
- Precision VirologicsCEO2016 — 2020Saint Louis
- Axia VenturesVenture Partner2013 — 2016
- NeuroHealing Pharmaceuticals Inc.President2003 — 2011Greater Boston Area
- Oridion MedicalVP Business Development1996 — 2003Jerusalem, Israel
Skills & more
+12 more
Business PlanningBusiness StrategyMarketing StrategyMarket ResearchPharmaceutical IndustryBiotechnologyMarket DevelopmentStrategyStrategic PlanningManagementProduct LaunchCommercializationLanguages English · Hebrew · Spanish
From Daniel's professional profile.
Frequently asked questions
- Who is Daniel Katzman?
- Daniel Katzman is CEO and founder of Unleash Immuno Oncolytics, which he built from formation through platform development to a transaction with TransCode Therapeutics (Nasdaq: RNAZ) granting TransCode exclusive worldwide rights to its oncolytic virus candidates UIO-524, UIO-525, and UIO-526 and associated intellectual property. The lead program, UIO-524, was designed to target malignant cells and the tumor microenvironment with an initial focus on muscle-invasive bladder cancer. He is also co-founder and Chairman of Asclepii, a Cleveland-based medical technology company developing regenerative medicine products for advanced wound care, where he works on corporate strategy, financing, partnerships, intellectual property, and commercialization.
- Where does Daniel Katzman work?
- Daniel Katzman is Executive at Precision Virologics.
- Where did Daniel Katzman go to school?
- Daniel Katzman studied at Universidad Nacional de La Plata (MSc, Biochemistry); Colegio Nacional de La Plata (Bachiller).
Same school
Also attended Universidad Nacional de La Plata10
+ 4 more
